Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,075,184
  • Shares Outstanding, K 3,100,443
  • Annual Sales, $ 45,811 M
  • Annual Income, $ 5,955 M
  • 60-Month Beta 0.47
  • Price/Sales 5.20
  • Price/Cash Flow 14.28
  • Price/Book 6.37
Trade AZN with:

Options Overview Details

View History
  • Implied Volatility 17.90% ( -3.14%)
  • Historical Volatility 18.53%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 31.19% on 10/16/23
  • IV Low 17.90% on 05/21/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 3,569
  • Volume Avg (30-Day) 11,061
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 153,000
  • Open Int (30-Day) 145,915

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.96
  • Number of Estimates 4
  • High Estimate 1.03
  • Low Estimate 0.89
  • Prior Year 1.08
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.38 +12.97%
on 04/22/24
78.38 unch
on 05/21/24
+9.83 (+14.34%)
since 04/19/24
3-Month
63.26 +23.90%
on 02/22/24
78.38 unch
on 05/21/24
+13.29 (+20.42%)
since 02/21/24
52-Week
60.47 +29.62%
on 02/12/24
78.38 unch
on 05/21/24
+3.59 (+4.80%)
since 05/19/23

Most Recent Stories

More News
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 28.52 (-0.04%)
ABBV : 164.18 (-0.23%)
JNJ : 152.18 (+0.60%)
RHHBY : 32.3600 (-1.25%)
GMAB : 29.36 (-1.11%)
AZN : 78.53 (+1.84%)
DSNKY : 35.1700 (-0.65%)
MRK : 131.52 (+0.40%)
LLY : 802.44 (+2.46%)
NVO : 134.43 (+1.14%)
Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead

Johnson & Johnson isn't the ultra-safe stock it used to be.

MMM : 104.84 (-0.35%)
JNJ : 152.18 (+0.60%)
AZN : 78.53 (+1.84%)
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 1.1150 (-0.45%)
CADL : 12.80 (+6.84%)
AZN : 78.53 (+1.84%)
HALO : 45.08 (+0.24%)
JANX : 47.02 (-2.02%)
ONC.TO : 1.54 (+1.99%)
Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles

USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer...

ONCY : 1.1150 (-0.45%)
ONC.TO : 1.54 (+1.99%)
CADL : 12.80 (+6.84%)
AZN : 78.53 (+1.84%)
HALO : 45.08 (+0.24%)
JANX : 47.02 (-2.02%)
AstraZeneca pulls its COVID-19 vaccine from the European market

The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled

$SPX : 5,306.23 (-0.04%)
$DOWI : 39,841.64 (+0.09%)
$IUXX : 18,631.59 (-0.23%)
AZN.LN : 12,306.000 (+1.74%)
AZN : 78.53 (+1.84%)
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END

MUSLF : 0.1810 (-3.83%)
MUSL.CN : 0.2550 (unch)
MRK : 131.52 (+0.40%)
PFE : 28.52 (-0.04%)
MRNA : 139.84 (-0.83%)
AZN : 78.53 (+1.84%)
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

MUSLF : 0.1810 (-3.83%)
MUSL.CN : 0.2550 (unch)
MRK : 131.52 (+0.40%)
PFE : 28.52 (-0.04%)
MRNA : 139.84 (-0.83%)
AZN : 78.53 (+1.84%)
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

/CNW/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...

ONCY : 1.1150 (-0.45%)
CELC : 16.81 (+0.06%)
OLMA : 9.50 (-0.21%)
BIO : 292.10 (+0.08%)
AZN : 78.53 (+1.84%)
ONC.TO : 1.54 (+1.99%)
Biotech's Developments in Race Against Rising Cancer Rates Revealed

USA News Group – According to a “highly troubling” new study, the rising number of cancer cases in young people is being attributed to “accelerated aging.” Further alarm is being spread by the...

ONCY : 1.1150 (-0.45%)
ONC.TO : 1.54 (+1.99%)
CELC : 16.81 (+0.06%)
OLMA : 9.50 (-0.21%)
BIO : 292.10 (+0.08%)
AZN : 78.53 (+1.84%)
Is This Dividend Stock a Buy Now?

With a robust portfolio, this top pharma stock is a good mix of growth and income.

AZN : 78.53 (+1.84%)
$SPX : 5,306.23 (-0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 78.05
2nd Resistance Point 77.64
1st Resistance Point 77.37
Last Price 78.53
1st Support Level 76.69
2nd Support Level 76.28
3rd Support Level 76.01

See More

Last Price 78.53
52-Week High 78.38
Fibonacci 61.8% 71.54
Fibonacci 50% 69.43
Fibonacci 38.2% 67.31
52-Week Low 60.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar